Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

Pre-Market: $69.46 +0.46 (0.67%) 9:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs

by Zacks Equity Research

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Here is Why Growth Investors Should Buy DexCom (DXCM) Now

by Zacks Equity Research

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.

QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.

DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why You Should Buy Bruker (BRKR) Stock Right Now

by Zacks Equity Research

Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.

Here's Why DexCom (DXCM) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues

by Zacks Equity Research

DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.

Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks Investment Ideas feature highlights: Vertiv, Align Technology and DexCom

by Zacks Equity Research

Vertiv, Align Technology and DexCom are part of the Zacks Investment Ideas article.

Benjamin Rains headshot

3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback

by Benjamin Rains

Long-term investors are often well-served to buy stocks amid bouts of weakness.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

by Zacks Equity Research

Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.

DexCom (DXCM) Stock Moves -1.16%: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $134.56, marking a -1.16% move from the previous day.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

by Urmimala Biswas

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.

DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

by Zacks Equity Research

DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Should First Trust Growth Strength ETF (FTGS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FTGS

Why the Market Dipped But DexCom (DXCM) Gained Today

by Zacks Equity Research

In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.